Vamil Divan analyst GUGGENHEIM

Currently out of the existing stock ratings of Vamil Divan, 390 are a BUY (68.42%), 165 are a HOLD (28.95%), 15 are a SELL (2.63%).

Vamil Divan

Work Performance Price Targets & Ratings Chart

Analyst Vamil Divan, currently employed at GUGGENHEIM, has had 55.27% of price targets met with an average potential upside of 42.87%, reached in 331 days on average.

Vamil Divan has documented 1,100 price targets and ratings displayed on 57 stocks. The coverage is on Healthcare, Financial Services, Technology sectors.

Most recent stock forecast was given on ABSI, Absci Corp.

Wall Street Analyst Vamil Divan

Analyst best performing recommendations are on ARAV (ARAVIVE).
The best stock recommendation documented was for KRTX (KARUNA THERAPEUTICS) on 8/9/2022. The price target of $276 was fulfilled within 3 days with a profit of $47.55 (20.81%), with a performance score of 69.38.

Average potential price target upside

ABBV AbbVie ACAD ACADIA Pharmaceuticals AGN Allergan plc ALKS Alkermes Plc AXSM Axsome Therapeutics BHVN Biohaven Pharmaceutical Holding Co Ltd EOLS Evolus KRTX Karuna Therapeutics LLY Eli Lilly and Company NBIX Neurocrine Biosciences PFE Pfizer PTLA Portola Pharmaceuticals SAGE Sage Therapeutic STSA Satsuma Pharmaceuticals TEVA Teva Pharma Industries Ltd ADR AIMT Aimmune Therapeutics BMY Bristol-Myers Squibb Company JNJ Johnson & Johnson CABA Cabaletta Bio CFRX ContraFect Corp RVNC Revance The AVTE Aerovate Therapeutics CALT Calliditas Therapeutics CRVS Corvus Pharmaceuticals ESPR Esperion Therapeutics GLPG Galapagos NV ADR GOSS Gossamer Bio IRWD Ironwood Pharmaceuticals KDNY Chinook Therapeutics MRK Merck mpany RLMD Relmada Therapeutics SCYX Scynexis TVTX Travere Therapeutics MGTA Magenta Therapeutics XERS Xeris Pharmaceuticals ANIP ANI Pharmaceuticals INSM Insmed ABSI Absci Corp ALDR Alder BioPharmaceuticals KROS Keros Therapeutics VERA Vera Therapeutics ACRX AcelRx Pharmaceuticals ARAV Aravive ASMB Assembly Biosciences MYGN Myriad Genetics SVRA Savara VALN Valneva SE ADR AMGN Amgen CFR Cullen/Frost Bankers ILMN Illumina KD Kyndryl Holdings KRT Karat Packaging PROK ProKidney Corp. SA Seabridge Gold ST Sensata Technologies Holding NV UNCY Unicycive Therapeutics ELOX Eloxx Pharmaceuticals

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 19-Feb-2026

$335

$39.97 (13.55%)

$325

1 days ago
(15-Nov-2026)

Buy Since 17-Nov-2020

$338

$42.97 (14.56%)

$282

15 days ago
(01-Nov-2026)

20/21 (95.24%)

$43.11 (14.62%)

335

Buy Since 07-Dec-2021

$340

$44.97 (15.24%)

$300

15 days ago
(01-Nov-2026)

11/13 (84.62%)

$45.11 (15.30%)

479

Buy Since 05-Apr-2022

$346

$50.97 (17.28%)

$310

15 days ago
(01-Nov-2026)

33/35 (94.29%)

$51.11 (17.33%)

486

Buy Since 15-Nov-2023

$325

$29.97 (10.16%)

$290

15 days ago
(01-Nov-2026)

32/33 (96.97%)

$30.11 (10.21%)

244

Show more analysts

Please expand the browser size to see the chart

Which stock is Vamil Divan most bullish on?

Potential upside of $79.84 has been obtained for INSM (INSMED)

Which stock is Vamil Divan most reserved on?

Potential downside of -$30.67 has been obtained for AMGN (AMGEN)

What Year was the first public recommendation made by Vamil Divan?

On 2008
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?